# Non-Preferred Drug > Non-Preferred Drug means a medication requiring pre-approval, not listed in a preferred directory, and subject to high cost-sharing or coverage limits. **Term:** Non-Preferred Drug **Last updated:** 2026-07-29 ## Definition ## What Non-Preferred Drug Means in a Contract A Non-Preferred Drug is a contractual classification used within pharmacy benefit agreements, health insurance policies, and employer-sponsored plan documents to describe a medication that is not included on a health plan's preferred formulary. Because it sits outside the preferred tier, the contract typically imposes higher member cost-sharing, such as elevated copayments or coinsurance, and may require pre-approval before the plan will cover the medication. The term functions as a mechanism for allocating financial risk between the plan sponsor, the insurer, and the covered individual. Contracts often distinguish tiers, such as generic, preferred brand, and non-preferred brand, with each tier carrying different reimbursement obligations. This tiering approach is a common feature of a [cost sharing agreement](https://www.genieai.co/en-us/template-type/cost-sharing-agreement) that governs how healthcare expenses are divided among the parties. Understanding this classification matters because it directly shapes the patient's financial exposure and the administrative steps required to obtain coverage. A drug labeled non-preferred is not necessarily excluded from coverage entirely, but the contract usually attaches conditions, limits, or higher costs to its use. ## How Non-Preferred Drug Is Defined or Measured Most agreements define Non-Preferred Drug by reference to a formulary maintained by the insurer or pharmacy benefit manager. The formulary is typically updated periodically, and the contract should specify how and when changes take effect, since a drug can move between preferred and non-preferred status without the member's direct involvement. Measurement of the classification often involves several contractual elements, including: - The specific formulary document or list referenced as the authoritative source - The cost-sharing percentage or fixed copay amount assigned to non-preferred status - Any prior authorization or step therapy requirements attached to the drug - Appeal or exception processes available if a preferred alternative is not clinically appropriate Some contracts also incorporate quantity limits or age restrictions tied to non-preferred status. Because these details vary by plan and by the law governing the contract, the precise definition must be read alongside any incorporated schedules, exhibits, or formulary references rather than relying on the term alone. ## Where Non-Preferred Drug Appears in Agreements The term appears most frequently in health insurance policies, pharmacy benefit management contracts, and employer benefit plan summaries. It is also common in administrative services agreements between employers and third-party administrators who manage prescription drug benefits on the employer's behalf. Within these documents, Non-Preferred Drug clauses typically sit near provisions addressing formulary management, utilization review, and member cost-sharing schedules. In sectors such as [healthcare](https://www.genieai.co/industry/healthcare) and [insurance](https://www.genieai.co/industry/insurance), these clauses are central to how benefit plans are priced and administered, since the classification directly influences claims volume and reimbursement rates. The concept can also surface in dispute resolution or appeals language, where a member challenges a non-preferred designation or seeks an exception based on medical necessity. Contracts sometimes cross-reference data handling obligations, particularly where formulary decisions rely on shared clinical or claims data, which is why some agreements are paired with a [data sharing agreement](https://www.genieai.co/en-us/template-type/data-sharing-agreement) governing how that information moves between parties. ## Why the Exact Wording Matters Precise wording matters because small differences in how a formulary is referenced, updated, or incorporated can significantly change a member's financial responsibility. If a contract fails to specify how formulary updates are communicated, disputes can arise over whether a drug's classification changed properly or whether the member received adequate notice. Ambiguity around exception processes is another area of concern. If the contract does not clearly state how a member can request a preferred-tier exception for a non-preferred drug, both the insurer and the member may face uncertainty during claims processing or appeals. Clear wording reduces the likelihood of disputes and supports consistent administration across large member populations. The stakes are also financial. Because non-preferred status often triggers substantially higher out-of-pocket costs, imprecise definitions can lead to unexpected expenses for members or unanticipated liability for plan sponsors, particularly if cost-sharing percentages or caps are not stated with sufficient clarity. ## Drafting Considerations When drafting or reviewing Non-Preferred Drug provisions, parties should ensure the formulary source is clearly identified, including how frequently it is updated and how those updates are communicated to affected members. It is also important to define the cost-sharing structure precisely, whether through a fixed dollar copay, a percentage coinsurance, or a combination, and to state any applicable caps. Drafters should address prior authorization and appeal procedures explicitly, including timelines for review and criteria for granting exceptions. Where multiple parties administer the benefit, such as an employer, insurer, and pharmacy benefit manager, responsibilities for formulary maintenance and member communication should be allocated clearly to avoid gaps in accountability. Finally, because formulary classifications can shift due to regulatory or market changes, contracts benefit from provisions addressing how such changes are handled mid-term, including notice requirements and any grandfathering protections for members already using a drug that moves to non-preferred status. ## Context ### Relevant circumstances - When a health plan applies higher cost-sharing to medications outside its formulary - If prior authorisation is required before a non-preferred drug is dispensed - Where prescribing decisions must consider cost-tier implications ### Relevant sectors - Healthcare - Insurance ## Relevant contract types - [Cost Sharing Agreement](https://www.genieai.co/en-us/template-type/cost-sharing-agreement) - [Data Sharing Agreement](https://www.genieai.co/en-us/template-type/data-sharing-agreement) --- This is the Markdown representation of [https://www.genieai.co/en-us/define/non-preferred-drug](https://www.genieai.co/en-us/define/non-preferred-drug), provided for AI agents and crawlers. The HTML page is canonical. See [/llms.txt](https://www.genieai.co/llms.txt) for the full content map.